HUE038399T2 - Brómhexint tartalmazó vizes kompozíció - Google Patents

Brómhexint tartalmazó vizes kompozíció

Info

Publication number
HUE038399T2
HUE038399T2 HUE11733637A HUE11733637A HUE038399T2 HU E038399 T2 HUE038399 T2 HU E038399T2 HU E11733637 A HUE11733637 A HU E11733637A HU E11733637 A HUE11733637 A HU E11733637A HU E038399 T2 HUE038399 T2 HU E038399T2
Authority
HU
Hungary
Prior art keywords
bromhexine
aqueous composition
aqueous
composition
Prior art date
Application number
HUE11733637A
Other languages
English (en)
Inventor
Uwe Scheuring
Bernd Plohmann
Annette Zamponi
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038399(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HUE038399T2 publication Critical patent/HUE038399T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
HUE11733637A 2010-07-12 2011-07-07 Brómhexint tartalmazó vizes kompozíció HUE038399T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10169236 2010-07-12

Publications (1)

Publication Number Publication Date
HUE038399T2 true HUE038399T2 (hu) 2018-10-29

Family

ID=43063562

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11733637A HUE038399T2 (hu) 2010-07-12 2011-07-07 Brómhexint tartalmazó vizes kompozíció

Country Status (26)

Country Link
US (1) US9220693B2 (hu)
EP (1) EP2593094B1 (hu)
JP (1) JP5979763B2 (hu)
KR (1) KR101943812B1 (hu)
CN (1) CN103052384B (hu)
AR (1) AR082381A1 (hu)
AU (1) AU2011278451B2 (hu)
BR (1) BR112013000537B1 (hu)
CA (1) CA2803471C (hu)
CL (1) CL2012003625A1 (hu)
CO (1) CO6680609A2 (hu)
CY (1) CY1120079T1 (hu)
DK (1) DK2593094T3 (hu)
EA (1) EA025640B1 (hu)
EC (1) ECSP13012384A (hu)
ES (1) ES2661973T3 (hu)
HR (1) HRP20180396T1 (hu)
HU (1) HUE038399T2 (hu)
LT (1) LT2593094T (hu)
MX (1) MX337454B (hu)
PE (1) PE20131063A1 (hu)
PL (1) PL2593094T3 (hu)
PT (1) PT2593094T (hu)
SG (1) SG187016A1 (hu)
SI (1) SI2593094T1 (hu)
WO (1) WO2012007352A1 (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103052384B (zh) 2010-07-12 2017-04-05 贝林格尔.英格海姆国际有限公司 包含溴己新的含水组合物
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
AU2013257706A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
JP6017249B2 (ja) * 2012-09-28 2016-10-26 小林製薬株式会社 経口投与用液体医薬組成物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103893116B (zh) * 2014-04-17 2015-12-09 河北仁合益康药业有限公司 一种盐酸溴己新口服液组合物
CA2949882C (en) * 2014-05-23 2023-02-28 Boehringer Ingelheim International Gmbh Cough syrup containing ambroxol hydrochloride
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用
CN111714477B (zh) * 2020-07-23 2021-06-15 山东迅达康兽药有限公司 祛痰组合物及其口服液制备方法
CN113109463B (zh) * 2021-03-16 2022-11-25 浙江工业大学 一种复方氯丙那林溴己新胶囊中有关物质的检测方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085784B2 (ja) 1987-06-17 1996-01-24 興和株式会社 シロツプ剤
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
CA2253260A1 (en) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
JP3800437B2 (ja) 1996-07-24 2006-07-26 大正製薬株式会社 苦味が軽減された液剤
JPH10101581A (ja) 1996-09-26 1998-04-21 Taisho Pharmaceut Co Ltd 塩酸ブロムヘキシンの安定化製剤及び安定化方法
JPH10306038A (ja) 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd ブロムヘキシン含有液剤
JP2000281562A (ja) * 1999-03-30 2000-10-10 Taisho Pharmaceut Co Ltd ゲル状組成物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
EP1121940A1 (en) * 2000-01-31 2001-08-08 New Pharma Research Sweden AB Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation
JP2002081562A (ja) 2000-09-05 2002-03-22 Kayaba Ind Co Ltd リリーフ弁
US6692725B2 (en) * 2001-02-19 2004-02-17 Daicel Chemical Industries, Ltd. Composition for oral care
US7138133B2 (en) * 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
JP5134802B2 (ja) 2005-09-29 2013-01-30 第一三共ヘルスケア株式会社 塩酸ブロムヘキシン含有量低下の防止方法
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
JP2008013542A (ja) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd 去痰又は気道杯細胞過形成抑制のための医薬組成物
CN100409835C (zh) * 2007-04-06 2008-08-13 张嵩 含有溴己新盐的组合物及大容量注射剂和注射剂制备方法
KR101025498B1 (ko) * 2008-05-02 2011-03-31 (주)이엘티사이언스 염산브롬헥신 경구용 액제 복합조성물 및 그 제조방법
CN103052384B (zh) 2010-07-12 2017-04-05 贝林格尔.英格海姆国际有限公司 包含溴己新的含水组合物

Also Published As

Publication number Publication date
CL2012003625A1 (es) 2013-05-31
US20130267605A1 (en) 2013-10-10
CA2803471A1 (en) 2012-01-19
KR101943812B1 (ko) 2019-01-31
JP5979763B2 (ja) 2016-08-31
CN103052384B (zh) 2017-04-05
EP2593094A1 (de) 2013-05-22
PT2593094T (pt) 2018-03-12
CN103052384A (zh) 2013-04-17
MX2013000417A (es) 2013-02-07
HRP20180396T1 (hr) 2018-04-20
PL2593094T3 (pl) 2018-05-30
ECSP13012384A (es) 2013-03-28
AU2011278451B2 (en) 2014-11-27
CY1120079T1 (el) 2018-12-12
MX337454B (es) 2016-03-07
LT2593094T (lt) 2018-03-26
EA025640B1 (ru) 2017-01-30
SG187016A1 (en) 2013-02-28
PE20131063A1 (es) 2013-10-12
DK2593094T3 (en) 2018-03-12
BR112013000537A2 (pt) 2016-05-24
JP2013531017A (ja) 2013-08-01
US9220693B2 (en) 2015-12-29
BR112013000537B1 (pt) 2021-07-27
EA201201659A1 (ru) 2013-06-28
AR082381A1 (es) 2012-12-05
ES2661973T3 (es) 2018-04-04
WO2012007352A1 (de) 2012-01-19
CA2803471C (en) 2019-01-15
EP2593094B1 (de) 2017-12-06
SI2593094T1 (en) 2018-04-30
KR20130100091A (ko) 2013-09-09
AU2011278451A1 (en) 2013-01-24
CO6680609A2 (es) 2013-05-31

Similar Documents

Publication Publication Date Title
LT2593094T (lt) Vandeninė kompozicija, apimanti bromheksiną
HK1186684A1 (en) Aqueous ophthalmic composition
AP3607A (en) Substituted imidazopyridazines
HK1171452A1 (en) Substituted pyrrolidine-2-carboxamides -2-
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
HK1210776A1 (en) Substituted sodium 1h-pyrazol-5-olate 1h--5-
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
EP2640832A4 (en) NEW ETHIOLOGICAL AGENT
IL222998A0 (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives